Navigation Links
Arbios Systems, Inc's Q2/07 Analyst Review Issued by Scimitar Equity Research, Inc.
Date:9/13/2007

For more information on ABOS.OB, please visit http://www.arbios.com .

Scimitar Equity Research, Inc. provides sponsored equity research of the healthcare industry for the institutional and investment communities. We certify that all the views expressed in this review, accurately reflect our personal views about ABOS.OB (NASDAQ: OTC: BB) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559-1080

fax: (617) 559-1083

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity Research, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. 3-D Imaging For Monitoring Reactor Systems, Power Plants
2. Working of Drug Department on Hold Without Drug Analyst
3. FDA may speed review of new drugs
4. Scientists review SARS
5. US Reviews Risks Of Tamiflu After 12 Children Die
6. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
7. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
8. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
9. Thumbs up in weight loss for vegetarian diets: scientific review
10. FDA Accords Priority Review For Pediatric Crohns Disease Drug
11. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5Video 3A Plan for Long Term Care Before the Crisis Hits 47797 1Video 3A Plan for Long Term Care Before the Crisis Hits 47797 2Video 3A Plan for Long Term Care Before the Crisis Hits 47797 3Video 3A Plan for Long Term Care Before the Crisis Hits 47797 4Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 1Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 12449 3Stepping up minority recruiting 47791 1Stepping up minority recruiting 47791 2Stepping up minority recruiting 47791 3